Quality of life and disease understanding: impact of attending a patient-centered cancer symposium.

The need for United States-based guidelines for myeloproliferative neoplasms.

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Profile of pomalidomide and its potential in the treatment of myelofibrosis.

Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.

Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I.

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

Impact of Inflammation on Myeloproliferative Neoplasm Symptom Development.

Emerging drugs for the treatment of myelofibrosis.

Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.